The American Red Cross has begun testing all blood, platelet and plasma donations for COVID-19 antibodies.

BioFlyte said on Tuesday that it has raised $1.25 million in seed funding, which the company said it will use to accelerate the development of its mass spectrometry-based biothreat detection device.

Kidney disease diagnostics firm RenalytixAI announced Friday it has received a clinical laboratory permit from the New York State Department of Health allowing the company to provide its KidneyIntelX test to residents of the state.

HTG Molecular said on Thursday that it has signed three new European distribution agreements to promote its products and services in Nordic and Eastern Europe countries.

An international team led by investigators at the Max Planck Institute for the Science of Human History (MPI-SHH) and the National Museums of Kenya has uncovered population patterns going back thousands of years in sub-Saharan Africa

Cue Health announced Wednesday that it has raised $100 million in Series C financing.

MilliporeSigma and 10x Genomics announced on Wednesday a collaboration on single-cell CRISPR screening workflows.

CareDx said on Wednesday that it has priced a planned $125 million public stock offering at $32 per share.

Researchers at Johns Hopkins University have developed a gene editing approach they call very fast CRISPR (vfCRISPR) that is capable of creating double-strand breaks (DSBs) in seconds, and at the submicrometer scale.

Roche subsidiary Foundation Medicine announced Friday it has acquired precision oncology firm Lexent Bio to help expand its liquid biopsy platforms and advance cancer care.

A recent genetic association study of people who are naturally thin has tied variants in the anaplastic lymphoma kinase (ALK) gene to thinness.

Genedrive said Friday that it has received the CE mark for its Genedrive 96 SARS-CoV-2 Kit and is making it available for sale in the European Union, including the UK, and other countries that accept the mark.

P23 Labs has received Emergency Use Authorization for its coronavirus PCR test from the US Food and Drug Administration.

The US Food and Drug Administration on Thursday granted separate Emergency Use Authorizations (EUAs) for PCR-based SARS-CoV-2 tests developed by South Korean diagnostic test makers BioCore, SolGent, and Seasun Biomaterials.

Agilent Technologies reported after the close of the market on Thursday that its second quarter 2020 revenue growth was flat year over year.